ARVO 2026: key results and trends

What the 4,943 abstracts at ARVO 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.

abstracts
4,943
drug-linked abstracts
1,218
companies
298
from Phase 3 studies
70

Drug-linked abstracts by phase

  • Phase 1 31
  • Phase 1/2 13
  • Phase 2 30
  • Phase 2/3 5
  • Phase 3 70
  • Phase 4 7

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Diabetic macular edema (DME)Roche

    faricimab

    Automated quantification of retinal fluid volume in patients with DME: analysis of faricimab vs aflibercept in YOSEMITE/RHINE

    Median time to first IRF volume <5 nL was week 72 for AFL Q8W after a median of 11 injections vs week 36 for FAR Q8W (hazard ratio [HR] 1.75 [95% CI: 1.49, 2.05]; P <0.0001) and T&E (HR 1.75 [95% CI: 1.49, 2.06]; P <0.0001) after a median of 7 and 6 injections, respectively.

    Read the abstract (opens in a new tab)
  2. Phase 3Bietti crystalline dystrophy (BCD)Chigenovo

    ZVS101e

    Interim Results of a Multicenter, Randomized, Controlled, Phase 3 Clinical Trial of a Single Subretinal Injection of ZVS101e in Patients with Bietti Crystalline Corneoretinal Dystroph

    The mean change in the MLMT score was 0.62 points in the treated group versus -0.44 points in the control group (p=0.017).

    Read the abstract (opens in a new tab)
  3. Phase 3Diabetic macular edema (DME)

    eflimrufusp alfa

    Intravitreal RC28-E, a Recombinant Fusion Protein with Simultaneous Inhibition of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor in patients with Diabetic Macular Edema: 52-week Results from a Randomized, Double-masked, Phase 3 Trial

    Analysis in moderately severe to severe non-proliferative diabetic retinopathy patients showed superior ≥3-step DRSS improvement with RC28-E vs aflibercept (27.8% vs 11.6% patients, respectively; nominal P = 0.0223).

    Read the abstract (opens in a new tab)
  4. Phase 3Exudative macular degeneration

    aflibercept

    Pigment epithelial detachment outcomes with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post hoc analysis

    At W96, the proportion of patients with serous PED decreased by 29.2% (2q8), 37.5% (8q12) and 36.7% (8q16) from BL, with fewer active injections with 8q12 and 8q16 versus 2q8 (9.7 and 8.2 vs 12.8) in the overall population.

    Read the abstract (opens in a new tab)
  5. Phase 3Geographic atrophy (GA)Apellis Pharmaceuticals

    pegcetacoplan

    Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD

    Eyes in the Early Treatment group demonstrated better outcomes: NSF GA growth was reduced by 31% with PM, preserving 3.87 mm 2 of retinal tissue (~2 disc areas), versus 26% and 1.93 mm 2 in the Delayed Treatment group.

    Read the abstract (opens in a new tab)
  6. Phase 2/3Geographic atrophy (GA)Astellas Pharma

    avacincaptad pegol

    Time-to-event analysis of driving eligibility maintenance following treatment with avacincaptad pegol in patients with geographic atrophy

    The risk probability of progressing to loss of driving eligibility in the study eye (≤60 letters) at 24 mths was 12.6% for ACP monthly or EOM vs 20.1% for sham, a 41% relative reduction in risk (hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.34,1.02; nominal P =0.0594).

    Read the abstract (opens in a new tab)
  7. Phase 2Diabetic macular edema (DME)Roche

    vamikibart

    Efficacy and safety of vamikibart in combination with ranibizumab in patients with DME: first results from the phase 2 BARDENAS trial

    VAM+RBZ showed a statistically significant difference in the adjusted mean BCVA change from baseline at W44/48 of +12.8 letters versus +9.4 letters for RBZ ( P =0.063 with a pre-established nominal 0.1 significance level).

    Read the abstract (opens in a new tab)
  8. Phase 2Age-related macular degeneration (AMD)

    QA102

    Oral QA102 Reduces Drusen Volume and Geographic Area Growth in Intermediate Atrophic Age-Related Macular Degeneration

    Compared to placebo, the mean change in drusen volume was reduced by 29.6% for subjects receiving QA102 200 mg (p=0.357) and 59.2% for QA102 400 mg (p=0.089).

    Read the abstract (opens in a new tab)
  9. Phase 2Diabetic macular edema (DME)

    tonabersat

    Oral Tonabersat Connexin-43 Modulator for Eyes with Diabetic Macular Edema with Good Vision (DRCR Protocol AN)

    The mean (SD) change in CST from baseline to 6 months was -15 (55) µm in the tonabersat group and +5 (51) µm in the placebo group (adjusted mean difference: -16 [95% CI, -34 to 2], P=0.08).

    Read the abstract (opens in a new tab)
  10. Phase 2Diabetic macular edema (DME)EyePoint Pharmaceuticals

    vorolanib

    VERONA phase 2 clinical trial of bioerodible EYP-1901 (vorolanib intravitreal insert) versus aflibercept for diabetic macular edema (DME): Visual, anatomic, and angiographic outcomes

    At W24, mean BCVA change from baseline was +7.1, +6.9, and +7.3 letters in the EYP-1901 2.7mg, 1.3mg, and afl arms, respectively.

    Read the abstract (opens in a new tab)
  11. Phase 1/2Dry eye syndrome (DED)IVIEW Therapeutics

    IVW-1001

    IVW-1001 ophthalmic eyelid wipe to treat dry eye patients, a Phase 1/2a Trial

    tCFS: 0.2% improved tCFS vs vehicle at Week 4 (study eye, p=0.0499) and Weeks 1–4 (fellow eye, p< 0.05).

    Read the abstract (opens in a new tab)

What the abstracts covered

Share of the 1,218 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Bispecific antibodies8%93 drug-linked abstracts

Top targets

  1. VEGFA18815%
  2. VEGFB726%
  3. ANGPT2706%
  4. PGF706%
  5. GR534%
  6. C3b262%
  7. ESR1262%
  8. C3232%
  9. CHRM3222%
  10. CHRM4212%

Top modalities

  1. Small molecules71559%
  2. Non-antibody therapeutic proteins22418%
  3. Monoclonal antibodies20917%
  4. Bispecific antibodies938%
  5. Peptides938%
  6. Gene therapies726%
  7. Oligonucleotide and RNA therapeutics595%
  8. Carbohydrate, lipid and polymer therapeutics464%

Top diseases

  1. Exudative macular degeneration13411%
  2. Age-related macular degeneration (AMD)13111%
  3. Diabetic macular edema (DME)998%
  4. Glaucoma968%
  5. Dry eye syndrome (DED)645%
  6. Diabetic retinopathy (DR)615%
  7. Geographic atrophy (GA)595%
  8. Ocular hypertension534%
  9. Retinal atrophy464%
  10. Retinitis pigmentosa (RP)393%

Most active companies

  1. Roche817%
  2. Regeneron Pharmaceuticals706%
  3. Pfizer615%
  4. Merck393%
  5. Genentech373%
  6. Apellis Pharmaceuticals212%
  7. GSK212%
  8. AbbVie202%
  9. Alcon202%
  10. AstraZeneca192%

Explore every ARVO 2026 result in Gosset

All 1,218 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call